title: Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer.
abstract: OBJECTIVE
  To evaluate the efficacy of bicyclol in preventing chemotherapy-induced liver damage.
  
  
  METHODS
  Patients ≥60 years of age with cancer were equally randomized into control (chemotherapy alone) or prophylactic (chemotherapy supplemented with 75 mg bicyclol, oral, daily) groups. Liver function indices were assessed immediately before treatment, during each therapy cycle and following treatment.
  
  
  RESULTS
  Of 306 patients enrolled, 300 patiets completed the study (n = 147 and n = 153; prophylactic and control groups, respectively). Incidence of grade I-IV elevation of serum transaminase and/or bilirubin was significantly lower in the prophylactic group (17.1%) compared with the control group (47.1%). Incidence of grade II-IV hepatic injury was also significantly lower in the prophylactic group (0.7%) than in the control group (12.4%).
  
  
  CONCLUSIONS
  Prophylactic bicyclol (75 mg daily) could significantly reduce the incidence and degree of chemotherapeutic agent-induced liver damage in elderly patients with cancer. Further studies are recommended with larger sample sizes and long-term follow up.
authors.affiliation: Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
authors.forename: Xiaoyuan
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China phoenixzhou@hotmail.com.
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
authors.forename: Shuchang
authors.initials: S
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Guan
authors.affiliation: Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
authors.forename: Yingyi
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Zhao
authors.affiliation: Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
authors.forename: Hongyan
authors.initials: H
authors.lastname: Ying
authors.affiliation: Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
authors.forename: Yanping
authors.initials: Y
authors.lastname: Zhou
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D065129:Pre-Exposure Prophylaxis / Q000379:methods; D011446:Prospective Studies; D000637:Transaminases / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; C477843:bicyclol; D000637:Transaminases; D001663:Bilirubin
keywords: Bicyclol; cancer; chemotherapy-induced liver injury; elderly people; hepatic injury; prophylaxis